Marker Therapeutics (MRKR) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to -$457.5 million.
- Marker Therapeutics' Retained Earnings fell 322.62% to -$457.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$457.5 million, marking a year-over-year decrease of 322.62%. This contributed to the annual value of -$447.0 million for FY2024, which is 245.97% down from last year.
- Per Marker Therapeutics' latest filing, its Retained Earnings stood at -$457.5 million for Q3 2025, which was down 322.62% from -$455.5 million recorded in Q2 2025.
- In the past 5 years, Marker Therapeutics' Retained Earnings registered a high of -$365.0 million during Q1 2021, and its lowest value of -$457.5 million during Q3 2025.
- For the 5-year period, Marker Therapeutics' Retained Earnings averaged around -$424.9 million, with its median value being -$433.0 million (2023).
- Per our database at Business Quant, Marker Therapeutics' Retained Earnings plummeted by 1178.29% in 2022 and then plummeted by 130.76% in 2024.
- Marker Therapeutics' Retained Earnings (Quarter) stood at -$398.1 million in 2021, then fell by 7.52% to -$428.0 million in 2022, then decreased by 1.92% to -$436.3 million in 2023, then decreased by 2.46% to -$447.0 million in 2024, then dropped by 2.34% to -$457.5 million in 2025.
- Its last three reported values are -$457.5 million in Q3 2025, -$455.5 million for Q2 2025, and -$451.5 million during Q1 2025.